In-space services & exploration
Serendipity Space
Bhubaneswar startup building re-entry satellites to crystallise drugs in orbit; its Alchemy factory module flew a stratospheric balloon test in March 2026.
Serendipity Space is a Bhubaneswar deep-tech startup, founded in 2024, that wants to manufacture pharmaceuticals off Earth. Its stated plan is to build reusable satellites with re-entry capability, crystallise protein and small-molecule drugs in orbit where gravity-induced defects do not form, and bring the product back to Earth. The three founders are Antariksh Parichha, chief executive, who took a master's in applied physics at the Technical University of Munich; Jivitesh Debata, chief technology officer, a computer scientist from the Rochester Institute of Technology; and Monica Ekal, chief of space systems, whose doctorate in space robotics is from Instituto Superior Tecnico in Portugal and who has worked at the German Aerospace Center and as a visiting scholar at NASA.
Campus Fund put in a pre-seed round announced on 4 July 2025. Neither side disclosed the amount, and the only valuation on the public record is third-party data: OfficeChai cited Dealroom figures placing the company at roughly Rs 22.5 crore post-money as of May 2025. At the time of the round the company said it had built and ground-tested two crystallisation modules and one formulation module, and that the ground validation had reached laboratory-grade crystallisation quality with proteins and small molecules. Its commercial argument was pharmaceutical rather than aerospace: an average net present value of $1.2 billion per novel drug, and an in-space manufacturing market the company projected to pass $10 billion by 2030.
The first flight test came in March 2026 and was reported publicly on 14 August 2026. An orbital-class satellite prototype carrying Alchemy, the company's autonomous pharmaceutical factory module, flew on a stratospheric balloon from the Tata Institute of Fundamental Research balloon facility in Hyderabad. The payload held commercial monoclonal antibody therapeutics, small molecules and additional proteins for drug discovery. Parichha said the module ran continuously under harsh conditions, executed crystallisation without human intervention, and preserved crystal integrity through a controlled return, touchdown and recovery; the flight also exercised the prototype's heatshield and avionics.
What the flight did not do is reach orbit. The company's own roadmap treats near-space balloon demonstrations as the step before full orbital missions in low Earth orbit, where its satellites would crystallise drugs and return them for use, and the reporting of the August 2026 announcement carries no date for that first orbital mission and no launch contract. The pre-seed amount likewise remains undisclosed. Serendipity Space points to Merck's work with NASA on an improved form of the cancer drug Keytruda aboard the International Space Station as the precedent for its chemistry, and argues that compressing drug development timelines of 12 to 15 years is where the commercial case sits.
What they build and operate
- Alchemy · Component · In development
Autonomous pharmaceutical factory module that crystallises drugs without human intervention; it ran through a stratospheric balloon flight and survived controlled return, touchdown and recovery.[5][6][7] - Reusable re-entry satellite · Satellite · In development
Orbital-class satellite platform with re-entry capability, intended to carry pharmaceutical processing payloads and bring them back from space; the prototype has flown on a balloon only.[10][9][6] - Microgravity pharmaceutical manufacturing service · Service · Announced
Planned low Earth orbit service crystallising protein and small-molecule drugs for pharmaceutical customers and returning the product to Earth.[6][3][10]
Funding
Milestones
- 2024
Founded in Bhubaneswar by Antariksh Parichha, Jivitesh Debata and Monica Ekal.[9][5] - 04 July 2025
Announced a pre-seed round from Campus Fund; the amount was not disclosed, and the company said two crystallisation modules and one formulation module had been ground-tested.[1][2][3] - October 2025
Technical team in place; OfficeChai reported a functional satellite prototype built in under four months, a claim it carries without attribution or independent support.[9] - March 2026
Flew Alchemy on a Tata Institute of Fundamental Research stratospheric balloon from Hyderabad, crystallising drug compounds in flight and recovering the payload.[9][8][5] - 14 August 2026
Disclosed the balloon test results; the flight reached near-space rather than orbit, and no orbital mission date was announced.[5][6][9]
Leadership
- Antariksh Parichha
Co-founder and chief executive officer (as of August 2026)[1][5][7] - Jivitesh Debata
Co-founder and chief technology officer (as of 04 July 2025)[1][2] - Monica Ekal
Co-founder and chief of space systems (as of 04 July 2025)[1][2]
Sources
The Tribune (Business Wire India press release via PTI)Serendipity Space Raises Pre-Seed Round from Campus Fund to Pioneer Space-Based Pharmaceutical Manufacturingtribuneindia.com
ThePrint (Business Wire India press release via ANI)Serendipity Space Raises Pre-Seed Round from Campus Fund to Pioneer Space-Based Pharmaceutical Manufacturingtheprint.in
BioSpectrum IndiaSerendipity Space raises Pre-Seed funding to pioneer space-based pharma manufacturingbiospectrumindia.com
OdishaPlusSerendipity Space Gets Pre-Seed Funding from Campus Fundodisha.plus
ThePrintOdisha-based start-up tests drug manufacturing in near-space missiontheprint.in
StartuppediaBhubaneswar-based Serendipity Space tests autonomous pharma factory Alchemy on a near-space missionstartuppedia.in
Indian Defence NewsOdisha Start-Up Demonstrates Space-Based Drug Manufacturing In Near-Space Missionindiandefensenews.in
OdishaPlusOdisha Startup's Breakthrough Mission in Space Medicineodisha.plus
OfficeChaiHow Bhubaneswar-based Startup Serendipity Space Is Making Medicines In Orbitofficechai.com
Serendipity SpaceOfficial siteserendipityspace.in
Coverage of Serendipity Space
In-space manufacturing
Serendipity Space details balloon-based drug-crystallisation test
The recovered Alchemy module exercised avionics and a return sequence, but the disclosed record does not establish microgravity production or orbital qualification.
Update this profile
Work at Serendipity Space or represent it? If something here is wrong or missing, email contact@spaceexploration.news with a public source for the change. Every profile edit is verified before it is published.
Request a profile change